CN113817059B - 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞 - Google Patents

用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞 Download PDF

Info

Publication number
CN113817059B
CN113817059B CN202111238201.1A CN202111238201A CN113817059B CN 113817059 B CN113817059 B CN 113817059B CN 202111238201 A CN202111238201 A CN 202111238201A CN 113817059 B CN113817059 B CN 113817059B
Authority
CN
China
Prior art keywords
gly
ser
leu
arg
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111238201.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN113817059A (zh
Inventor
唐纳德·E·斯汤顿
陆满晴
李志杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiali Medical Technology Guangzhou Co ltd
Original Assignee
Jiali Medical Technology Guangzhou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiali Medical Technology Guangzhou Co ltd filed Critical Jiali Medical Technology Guangzhou Co ltd
Priority to CN202111238201.1A priority Critical patent/CN113817059B/zh
Publication of CN113817059A publication Critical patent/CN113817059A/zh
Application granted granted Critical
Publication of CN113817059B publication Critical patent/CN113817059B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202111238201.1A 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞 Active CN113817059B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111238201.1A CN113817059B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276855P 2016-01-09 2016-01-09
US62/276,855 2016-01-09
PCT/US2017/012648 WO2017120557A1 (en) 2016-01-09 2017-01-07 Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment
CN202111238201.1A CN113817059B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
CN201780005758.6A CN108778327B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780005758.6A Division CN108778327B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞

Publications (2)

Publication Number Publication Date
CN113817059A CN113817059A (zh) 2021-12-21
CN113817059B true CN113817059B (zh) 2024-03-08

Family

ID=59274048

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202111238201.1A Active CN113817059B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
CN201780005758.6A Active CN108778327B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
CN202111238599.9A Active CN113912725B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
CN202111238485.4A Active CN113817060B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201780005758.6A Active CN108778327B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
CN202111238599.9A Active CN113912725B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
CN202111238485.4A Active CN113817060B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞

Country Status (8)

Country Link
US (1) US11207419B2 (https=)
EP (1) EP3400013A4 (https=)
JP (3) JP6974348B2 (https=)
KR (1) KR20180127966A (https=)
CN (4) CN113817059B (https=)
AU (1) AU2017206089B2 (https=)
IL (1) IL260474B (https=)
WO (1) WO2017120557A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021524576A (ja) * 2018-05-16 2021-09-13 アーベル リミテッドＡｒｂｅｌｅ Ｌｉｍｉｔｅｄ がんの診断及び治療のための組成物及び方法
US20210115152A1 (en) * 2018-05-16 2021-04-22 Arbele Limited Composition of bispecific antibodies and method of use thereof
JP7812549B2 (ja) * 2019-02-21 2026-02-10 アーベル リミテッド 人工免疫監視キメラ抗原受容体（ａｉ－ｃａｒ）及びそれを発現する細胞
TWI717880B (zh) 2019-10-24 2021-02-01 中國醫藥大學附設醫院 Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物
US20230340119A1 (en) * 2019-12-05 2023-10-26 Arbele Corp Composition of triax antibodies and method of making and using thereof
JP2024523033A (ja) * 2021-06-17 2024-06-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の三重特異的結合分子
EP4413366A4 (en) * 2021-10-08 2025-09-10 Tiberias Tech Hk Limited TIBTECH METHODS AND COMPOSITIONS FOR THE DETECTION OF CDH17
CA3240301A1 (en) * 2021-12-07 2023-06-15 Dennis Slamon Cdh17 antibodies and methods of treating cancer
CN113999308B (zh) * 2021-12-30 2022-03-11 深圳市人民医院 靶向钙粘蛋白17的纳米抗体及其应用
AU2023377353A1 (en) 2022-11-11 2025-05-22 Ospedale San Raffaele S.R.L. Cdh17 car
CN120712286A (zh) * 2023-02-23 2025-09-26 翰森生物有限责任公司 抗体、抗原结合片段和使用方法
WO2024220437A2 (en) * 2023-04-17 2024-10-24 Arbele Limited Compositions and methods for determining the effects of t cell engager
WO2024240227A1 (en) * 2023-05-24 2024-11-28 Multitude Therapeutics Inc. Antibodies and antibody-drug conjugates thereof
AU2024347590A1 (en) * 2023-09-22 2026-04-09 Lepu Biopharma Co., Ltd. Anti-cdh17 antibodies and uses thereof
CN120137019A (zh) * 2023-12-11 2025-06-13 东莞市朋志生物科技有限公司 一种抗糖化血红蛋白HbA1c的抗体及其应用
CN120230211A (zh) * 2023-12-29 2025-07-01 广东菲鹏制药股份有限公司 抗cdh17抗体或其抗原结合片段及其应用
CN120988128A (zh) * 2024-05-20 2025-11-21 杭州中美华东制药有限公司 抗cdh17抗体、其抗体药物偶联物及其用途
WO2025242099A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 针对cdh17的抗体偶联药物及其用途
WO2025242100A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 针对cdh17的抗体及其用途
WO2025252211A1 (zh) * 2024-06-07 2025-12-11 映恩生物制药（苏州）有限公司 抗人cdh17抗体
WO2026015644A1 (en) * 2024-07-10 2026-01-15 The Trustees Of The University Of Pennsylvania Cadherin-17 targeting antigen biding polypeptides, chimeric antigen receptors, car-t cells and methods of treating cadherin-17 positive cancers
US20260078179A1 (en) * 2024-07-18 2026-03-19 Novarock Biotherapeutics, Ltd. Cdh17 antibodies and uses thereof
WO2026046327A1 (en) * 2024-08-29 2026-03-05 Utc Therapeutics (Shanghai) Co., Ltd. Cdh17 targetting antibodies, chimeric antigen receptors, and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012054084A2 (en) * 2010-10-20 2012-04-26 Oxford Biotherapeutics Ltd. Antibodies
CN102482353A (zh) * 2009-04-20 2012-05-30 牛津生物疗法有限公司 特异于钙粘素-17的抗体
CN102483414A (zh) * 2008-10-09 2012-05-30 香港大学 作为肝癌诊断标记和治疗靶标的钙黏着蛋白-17

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
CN102936287B (zh) 2008-02-08 2015-09-09 伊缪纳斯制药株式会社 能够特异性结合Aβ寡聚体的抗体及其应用
US8435749B2 (en) * 2008-06-30 2013-05-07 Oncotherapy Science, Inc. Anti-CDH3 antibodies labeled with radioisotope label and uses thereof
LT2535358T (lt) * 2010-02-10 2018-03-26 Fujifilm Ri Pharma Co., Ltd. Radioaktyvus metalu žymėtas anti-kadherino antikūnas
RS57215B1 (sr) * 2010-07-15 2018-07-31 Adheron Therapeutics Inc Humanizovana antitela koja ciljaju ec1 domen kadherina-11 i kompozicije i postupci koji su u vezi sa njima
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
EP2948478B1 (en) * 2013-01-25 2019-04-03 Amgen Inc. Antibodies targeting cdh19 for melanoma
IL263466B2 (en) * 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102483414A (zh) * 2008-10-09 2012-05-30 香港大学 作为肝癌诊断标记和治疗靶标的钙黏着蛋白-17
CN102482353A (zh) * 2009-04-20 2012-05-30 牛津生物疗法有限公司 特异于钙粘素-17的抗体
WO2012054084A2 (en) * 2010-10-20 2012-04-26 Oxford Biotherapeutics Ltd. Antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CDH17在肿瘤发生发展中的作用;潘地铃;;中国医疗前沿;第07卷(第08期);第10-11页 *
Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma;Nikki P Lee等;Biochim Biophys Acta actions Search in PubMed Search in NLM Catalog Add to Search .;第1806卷(第2期);第138-145页 *

Also Published As

Publication number Publication date
JP6974348B2 (ja) 2021-12-01
EP3400013A1 (en) 2018-11-14
CN113912725B (zh) 2024-03-08
JP2023109790A (ja) 2023-08-08
EP3400013A4 (en) 2019-09-11
US11207419B2 (en) 2021-12-28
IL260474B (en) 2020-08-31
CN113912725A (zh) 2022-01-11
JP7275232B2 (ja) 2023-05-17
JP2019518721A (ja) 2019-07-04
US20190046655A1 (en) 2019-02-14
AU2017206089A1 (en) 2018-08-30
CN108778327A (zh) 2018-11-09
CN113817059A (zh) 2021-12-21
CN113817060B (zh) 2024-03-08
JP2022036939A (ja) 2022-03-08
CN113817060A (zh) 2021-12-21
WO2017120557A1 (en) 2017-07-13
JP7482287B2 (ja) 2024-05-13
KR20180127966A (ko) 2018-11-30
AU2017206089B2 (en) 2020-04-16
CN108778327B (zh) 2021-11-05

Similar Documents

Publication Publication Date Title
CN113817059B (zh) 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
CN112512575B (zh) 双特异性抗体组合物及其使用方法
US9334330B2 (en) Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers
EP3572427A1 (en) Bcma-targeting antibody and use thereof
EP4455266A1 (en) Fully human antibody targeting gprc5d and chimeric antigen receptor (car) and use thereof
JP2024513262A (ja) Ｎｋｐ４６及びｃｄ３８を標的とする二重特異性抗体、並びにその使用方法
HK1262482A1 (en) Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment
EP4567046A1 (en) Antibody targeting egfrviii and use thereof in cell immunotherapy
EP4588939A1 (en) Interleukin-13 receptor subunit alpha-2 (il13ralpha2) targeting moieties for the treatment and prevention of il13ralpha2-positive cancer
HK1262482B (zh) 用於癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
TW202535920A (zh) 程序性死亡配體1（pd-l1）嵌合抗原受體及其應用
WO2024176224A1 (en) Antibodies against hla-e and use thereof
HK40010512A (en) Bcma-targeting antibody and use thereof
HK40010512B (en) Bcma-targeting antibody and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant